Statement on Seasonal Influenza Vaccine
- The Canadian recommendations for Influenza vaccine are stated by the National Advisory Committee on Immunization (NACI) each year. Provinces take this information into consideration when implementing their own recommendations.
Co-Administration of Vaccines with the COVID-19 Vaccines
A statement has been released by the National Advisory Committee on Immunization (NACI) recommending that COVID-19 vaccines can now be co-administered with other vaccines, including the influenza (flu) vaccine, in individuals 12 years of age and older. NACI has determined that a precautionary approach is no longer necessary and recommends that COVID-19 vaccines may be administered concomitantly with, or at any time before of after, non-COVID-19 vaccines, including live, non-live, adjuvanted, or unadjuvanted vaccines.
Learn more →
On November 19, 2021, NACI released Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age which advises that children receive the Pfizer-BioNTech COVID-19 vaccine (10 mcg) at least 14 days before or after another vaccine as a precautionary approach.
Learn more →
2021-2022 Universal Influenza Immunization Program Implementation Package
Components of 2021-2022 Influenza Vaccine
The World Health Organization recommends which components should be included in influenza vaccines each year. For the 2021-2022 influenza season, in the Northern Hemisphere, these will be:
Egg-based QIVs (FluLaval Tetra, FLUZONE Quadrivalent ®, Afluria Tetra® , FLUZONE High-Dose Quadrivalent®)
- An A/Victoria/2570/2019 (H1N1)pdm09-like virus;
- An A/Cambodia/e0826360/2020 (H3N2)-like virus;
- A B/Washington/02/2019-like virus (B/Victoria lineage)-like virus;
- A B/Phuket/3073/2013 (B/Yamagata lineage)- like virus
Egg-based TIVs (Fluad®)
- An A/Victoria/2570/2019 (H1N1) pdm09-like virus;
- An A/Cambodia/e0826360/2020 (H3N2)-like virus;
- A B/Washington/02/2019-like virus (B/Victoria lineage)-like virus
Cell-or recombinant-based Vaccines (Flucelvax Quad®)
- An A/Cambodia/e0826360/2020 (H3N2)-like virus;
- An A/Wisconsin/588/2019 (H1N1) pdm09-like virus;
- A B/Washington/02/2019-like virus (B/Victoria lineage)-like virus;
- A B/Phuket/3073/2013 (B/Yamagata lineage)- like virus
Influenza Vaccine Product Monographs
Seasonal Influenza Vaccine Consent Form
Influenza Immunization Reporting Forms
For the 2021-2022 Universal Influenza Immunization Program, the Ministry of Health no longer requires vaccine utilization reports from facilities that participate.
Reporting Requirements for Health Care Worker Influenza Immunization (Long-Term Care Homes and Public Hospitals)
- Long-term care homes and publicly hospitals are required to report health care worker immunization rates to the Health Unit by mid to late January 2022. Further details regarding collection of health care worker coverage rates, including forms, will be provided when available.
Reporting Requirements for Long-Term Care Home Resident Influenza Immunization
- Long-term care homes are required to report resident immunization rates to the Health Unit by mid to late January 2022. Further details regarding collection of resident coverage rates, including forms, will be provided when available.
Influenza Outbreak Tools
Line Lists
Specimen Collection and Testing
Antivirals
Surveillance
Local Surveillance
Provincial Surveillance
National Surveillance
Resources
COVID-19 Pandemic Considerations
The COVID-19 pandemic creates a series of challenges for the delivery of the seasonal influenza immunization program. The following resources have been developed by NACI to address these challenges in various health care settings.
For additional guidance and setting specific resources, including others on immunization, visit COVID-19 Guidance and Resources for Health Care Providers and Institutions.
Influenza Surveillance Reports
BrowseAloud
